Cook takes AAA (abdominal aortic aneurysm) graft to the US:
This article was originally published in Clinica
The US FDA has given Cook the all-clear to sell its Zenith endovascular graft system for treating abdominal aortic aneurysm (AAA). The third-generation device, claims the firm, has already captured "major market share positions" in Europe, Australia and elsewhere in more than 35 other countries where it has been available commercially for several years. US sales are expected to start immediately. Advanced features of the Zenith system include suprarenal fixation and a graft design that allows treatment of a wide variety of patient anatomies, adds the Bloomington, Indiana firm.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.